Mycovia Pharmaceuticals, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.mycovia.com
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Phase 3
Completed
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Mycovia Pharmaceuticals Inc.
- Target Recruit Count
- 219
- Registration Number
- NCT03840616
- Locations
- ๐บ๐ธ
27, Idaho Falls, Idaho, United States
๐บ๐ธ36, Miami, Florida, United States
๐บ๐ธ62, Chicago, Illinois, United States
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Phase 3
Completed
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Mycovia Pharmaceuticals Inc.
- Target Recruit Count
- 425
- Registration Number
- NCT03561701
- Locations
- ๐บ๐ธ
31223, Winston-Salem, North Carolina, United States
๐บ๐ธ31218, Jackson, Tennessee, United States
๐บ๐ธ31232, Frisco, Texas, United States
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Phase 3
Completed
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Mycovia Pharmaceuticals Inc.
- Target Recruit Count
- 438
- Registration Number
- NCT03562156
- Locations
- ๐บ๐ธ
31143, Sarasota, Florida, United States
๐บ๐ธ31132, Greensboro, North Carolina, United States
๐บ๐ธ31134, Philadelphia, Pennsylvania, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath